Extended Data Fig. 4: Immune cell types and signature markers.
From: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Distribution of scores for immune cell types (top row), immune checkpoint genes and biomarkers (second row), functional orientation markers (third row) and signature scores (last row). Shown are boxplots for each TME subtype. Dots denote individual values. N = 38 independent patient samples in total. Central bars indicate medians, the box defines the upper and lower quartiles of the distribution, and whiskers define the 1.5× IQR. All comparisons have p < 0.05 unless specifically indicated with ns (p > 0.05).
